UOB stock price jumps in Singapore afternoon trade as analysts flag a “catch-up” play
22 January 2026
1 min read

UOB stock price jumps in Singapore afternoon trade as analysts flag a “catch-up” play

Singapore, Jan 22, 2026, 14:49 SGT — Regular session

  • UOB shares outperform in Thursday trade in Singapore
  • Broker upgrade and capital actions keep the bank in focus
  • Investors look to earnings guidance as rate bets shift

United Overseas Bank’s shares were up 2.0% at S$37.52 by 2:39 p.m. in Singapore on Thursday, extending gains that earlier took the stock close to its recent highs. 1

The move matters now because bank stocks are sliding into earnings season with investors trying to price a different rates backdrop. When funding costs stop rising, the lift from higher loan yields can fade fast.

For UOB, the next test is whether it can defend net interest margin — the spread between what it earns on loans and what it pays on deposits — while keeping loan growth steady. Traders also track provisions, cash set aside for bad loans, because that can swing quarterly earnings.

Talk on desks has been about positioning more than any single headline. Still, fresh broker research has helped pull buyers back into a stock that had been moving sideways for weeks.

Macquarie analyst Jayden Vantarakis upgraded UOB to “outperform” in a Wednesday note and lifted his target price to S$41, calling it a “relative-value catch up play” as headwinds ease into earnings season. He wrote that lower rates were a “double-edged sword” for 2026 revenue, while pointing to firmer lending data and a path for provisions to normalise after one-offs. 2

A stock exchange filing on Wednesday also showed UOB bought back 38,000 shares on Jan. 20 for about S$1.4 million, cancelling the shares the same day. 3

In a separate funding update dated Jan. 21, UOB said its Sydney branch priced two Australian dollar senior unsecured note tranches due 2031: a A$750 million floating-rate deal at three-month BBSW plus 0.72% and a A$1.25 billion fixed-rate note paying 5.023%. BBSW is an Australian money-market benchmark rate.

But the setup can flip. Faster or deeper rate cuts than investors expect would squeeze lending spreads, while a turn in asset quality would push provisions higher and blunt any valuation rerating.

The other uncertainty is fees. Non-interest income — wealth fees, cards and markets revenue — can swing sharply quarter to quarter, and it often decides whether a bank beats or misses estimates when margins are tight.

UOB’s investor calendar shows it is scheduled to report FY25/4Q25 results on Feb. 24, with the bank flagging the date as indicative. 4

That print is the next hard catalyst. Investors will be watching for management’s margin and credit-cost assumptions for 2026, and whether capital returns stay on track as funding and growth conditions reset.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
CapitaLand Investment (SGX:9CI) pops back above S$3, eyes 52-week high in Singapore trade
Previous Story

CapitaLand Investment (SGX:9CI) pops back above S$3, eyes 52-week high in Singapore trade

ST Engineering stock slips 1.7% in Singapore as Qatar services deal and $151B U.S. contract hit the tape
Next Story

ST Engineering stock slips 1.7% in Singapore as Qatar services deal and $151B U.S. contract hit the tape

Go toTop